William L. Moore
All posts from William L. Moore
William L. Moore in Insider trading,

Deutsche Takes A Look At Johnson & Johnson's Patent Woes

Deutsche Bank maintained its Buy rating on Johnson & Johnson  despite a federal judge invalidated the company's patent for blockbuster rheumatoid arthritis drug, Remicade.

The ruling is in favor of Celltrion and Pfizer Inc.  which can now sell its Remicade biosimilar Inflectra on or after October 3.

The Remicade patent, which is set to expire in the US in September 2018, was related to the method of action of anti-human tumor necrosis factor-alpha antibodies.

"In our view, it is unclear whether or not this ultimately comes to fruition," analyst Kristen Stewart wrote in a note.

Johnson & Johnson plans to appeal the ruling and views any commercial launch prior to the outcome of the appeals process as an "at risk" launch.